Milestone Pharmaceuticals Inc. Common Shares
MIST
Closed
$1.28
Closed
-(-)
At close
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply
About
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 38 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Key stats
Open
$1.23
Volume
809.25K
Market cap
$151.89M
Prev. close
$1.31
Impl / hst vl
-
Open interest
$0.00
$1.23
Day’s Range
$1.28
$1.00
52W Range
$2.34
Valuation
44
Valuation score
Fairly Valued
P/E
-
P/S
86.88
P/B
4.30
Current ratio
9.18
Debt / Equity
1.80
ROE
-169.03%
Gross margin
-
Income growth
49.73%
FCF growth
23.28
Analysts estimates
Consensus rating
Buy
The average rating from top 7 analysts indicates that stock is expected to perform in line with the market
Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$6.46
The top 8 analysts forecasts that 12-month price may increase by 404.68%, with a low of $2.02 and a high of $8.40
$2.02
Low
$6.46
Avg
$8.40
High
Current price
Earnings
Q1 ‘26 revenue
$238.00K
Q1 ‘26 net income
-$26.07M
Revenue
Net income
Previous EPS
-$0.20
Estimate EPS
-$0.20
Actual EPS
Estimate EPS
Explore the Healthcare sector
Get professional financial guidance
Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply